BMP15 and polycystic ovary syndrome: In the PCOS group (24.85±7.03), BMP15 immunoreactivity in the follicular developing stages was significantly decreased (p<0.05) compared to the control group (31.12±11.05) and the vehicle group (29.99±10.72; Table 1, Figure 3b).